BR112012020604A2 - "aminotiazolonas como moduladores do receptor alfa-relacionado ao estrôgenio" - Google Patents
"aminotiazolonas como moduladores do receptor alfa-relacionado ao estrôgenio"Info
- Publication number
- BR112012020604A2 BR112012020604A2 BR112012020604A BR112012020604A BR112012020604A2 BR 112012020604 A2 BR112012020604 A2 BR 112012020604A2 BR 112012020604 A BR112012020604 A BR 112012020604A BR 112012020604 A BR112012020604 A BR 112012020604A BR 112012020604 A2 BR112012020604 A2 BR 112012020604A2
- Authority
- BR
- Brazil
- Prior art keywords
- arthritis
- disease
- cartilage
- chronic
- injury
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
aminotiazolonas como moduladores do receptor alfa-relacionado ao estrôgenio. a presente invenção refere-se a compostos da fórmula (i), método para preparar estes compostos, composições, intermediários e derivados dos mesmos, e para tratar uma condição que inclui, mas não se limita a, espondilite anquilosante, arterosclerose, artrite (como artrite reumatoide, artrite infecciosa, artrite infantil, artrite psoriática, artrite reativa), doenças relacionadas aos ossos (incluindo aquelas relacionadas à formação óssea), câncer de mama (incluindo aqueles que não respondem a terapia antiestrogênica), distúrbios cardiovasculares, doença relacionada a cartilagem (como lesão/perda de cartilagem, degeneração de cartilagem, e aquelas ralacionadas a formação cartilaginosa), controdysplasia, chodrosarcoma, lesão crônica nas costas, bronquite crônica, doença inflamatória das vias respiratórias crônica, doença pulmonar obstrutiva crônica, diabetes, distúrbios da homeostase energética, gota, pseudogota, distúrbios lipídicos, síndrome metabólica, mieloma múltiplo, obesidade, osteoartrite, osteogênese imperfeita, metástase óssea osteolítica, osteomalacia, osteoporose, doença de paget, doença periodontal, polimyalgia reumática, síndrome de reiter, lesão de esforço repetitivo, hiperglicemia, nível elevado de glicose sanguínea, e resistência á insulina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30517710P | 2010-02-17 | 2010-02-17 | |
PCT/US2011/024999 WO2011103130A1 (en) | 2010-02-17 | 2011-02-16 | Aminothiazolones as estrogen related receptor-alpha modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012020604A2 true BR112012020604A2 (pt) | 2019-09-24 |
Family
ID=43920677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012020604A BR112012020604A2 (pt) | 2010-02-17 | 2011-02-16 | "aminotiazolonas como moduladores do receptor alfa-relacionado ao estrôgenio" |
Country Status (14)
Country | Link |
---|---|
US (1) | US8426604B2 (pt) |
EP (1) | EP2536716B1 (pt) |
JP (1) | JP2013519729A (pt) |
KR (1) | KR20120133383A (pt) |
CN (1) | CN102869660A (pt) |
AR (1) | AR080206A1 (pt) |
AU (1) | AU2011218268A1 (pt) |
BR (1) | BR112012020604A2 (pt) |
CA (1) | CA2789753A1 (pt) |
MX (1) | MX2012009528A (pt) |
RU (1) | RU2012139459A (pt) |
TW (1) | TW201130831A (pt) |
UY (1) | UY33230A (pt) |
WO (1) | WO2011103130A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2013051632A1 (ja) * | 2011-10-04 | 2015-03-30 | 武田薬品工業株式会社 | 含窒素縮合複素環化合物 |
SG11201406032TA (en) | 2012-03-26 | 2014-11-27 | Nippon Chemiphar Co | Prophylactic or therapeutic agent for giant cell tumors occuring in bone and soft tissue or for chondrosarcoma |
JP6527822B2 (ja) | 2013-09-25 | 2019-06-05 | 日本ケミファ株式会社 | 骨・軟部に発生する巨細胞性腫瘍、軟骨肉腫または骨肉腫の予防、治療または転移の予防のための薬剤、動脈塞栓術用局所注入剤、および、人工骨 |
TW201811752A (zh) * | 2016-09-06 | 2018-04-01 | 比利時商健生藥品公司 | 用作升糖素受體拮抗劑之吲唑衍生物 |
CN112538038B (zh) * | 2019-09-20 | 2022-05-20 | 暨南大学 | 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1075072C (zh) * | 1995-06-02 | 2001-11-21 | 圣诺菲—合成实验室公司 | 噁唑烷酮衍生物及其制法和用途 |
AU5348098A (en) | 1996-12-17 | 1998-07-15 | Quadrant Holdings Cambridge Limited | Melanocortins |
JP2008506691A (ja) | 2004-07-14 | 2008-03-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | エストロゲン関連受容体−アルファに媒介される疾患の処置のためのアリーリデン |
WO2006047269A2 (en) * | 2004-10-22 | 2006-05-04 | Exelixis, Inc. | Pharmaceutical compositions |
UA98484C2 (ru) * | 2007-03-07 | 2012-05-25 | Янссен Фармацевтика Н.В. | ЗАМЕЩЕННЫЕ ФЕНОКСИАМИНОТИАЗОЛОНЫ КАК МОДУЛЯТОРЫ α-РЕЦЕПТОРА ЭСТРОГЕНА |
-
2011
- 2011-02-16 AU AU2011218268A patent/AU2011218268A1/en not_active Abandoned
- 2011-02-16 WO PCT/US2011/024999 patent/WO2011103130A1/en active Application Filing
- 2011-02-16 BR BR112012020604A patent/BR112012020604A2/pt not_active IP Right Cessation
- 2011-02-16 KR KR1020127023756A patent/KR20120133383A/ko not_active Application Discontinuation
- 2011-02-16 TW TW100105005A patent/TW201130831A/zh unknown
- 2011-02-16 EP EP11705404.9A patent/EP2536716B1/en active Active
- 2011-02-16 US US13/028,266 patent/US8426604B2/en active Active
- 2011-02-16 JP JP2012553980A patent/JP2013519729A/ja not_active Withdrawn
- 2011-02-16 MX MX2012009528A patent/MX2012009528A/es not_active Application Discontinuation
- 2011-02-16 CA CA2789753A patent/CA2789753A1/en not_active Abandoned
- 2011-02-16 CN CN2011800194232A patent/CN102869660A/zh active Pending
- 2011-02-16 RU RU2012139459/04A patent/RU2012139459A/ru not_active Application Discontinuation
- 2011-02-17 AR ARP110100487A patent/AR080206A1/es unknown
- 2011-02-17 UY UY0001033230A patent/UY33230A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2789753A1 (en) | 2011-08-25 |
AU2011218268A1 (en) | 2012-09-06 |
RU2012139459A (ru) | 2014-03-27 |
KR20120133383A (ko) | 2012-12-10 |
EP2536716A1 (en) | 2012-12-26 |
WO2011103130A1 (en) | 2011-08-25 |
WO2011103130A8 (en) | 2012-09-13 |
US20110200586A1 (en) | 2011-08-18 |
MX2012009528A (es) | 2013-01-14 |
EP2536716B1 (en) | 2014-05-21 |
UY33230A (es) | 2011-08-31 |
JP2013519729A (ja) | 2013-05-30 |
US8426604B2 (en) | 2013-04-23 |
TW201130831A (en) | 2011-09-16 |
CN102869660A (zh) | 2013-01-09 |
AR080206A1 (es) | 2012-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0808662B8 (pt) | tiazolidinadiona n-alquiladas de fenóxi substituída, seu uso, composição farmacêutica que as compreende e processo para preparar a referida composição farmacêutica | |
ECSP099614A (es) | Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionado con el estrogeno | |
EA200970839A1 (ru) | ЗАМЕЩЁННЫЕ ФЕНОКСИ АМИНОТИАЗОЛОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ РОДСТВЕННОГО ЭСТРОГЕНОВОМУ РЕЦЕПТОРУ РЕЦЕПТОРА-α | |
BR112012020604A2 (pt) | "aminotiazolonas como moduladores do receptor alfa-relacionado ao estrôgenio" | |
TW201144303A (en) | Aminothiazolones as estrogen related receptor-α modulators | |
Pagenstert et al. | Realignment surgery for valgus ankle osteoarthritis. | |
JP2012506473A5 (pt) | ||
BR112017010995A2 (pt) | composições, utilização de uma composição e método para a promoção da saciedade | |
Hintermann et al. | Joint-preserving surgery of asymmetric ankle osteoarthritis with peritalar instability. | |
BR112013024040A2 (pt) | compósitos de poliuretano produzidos por processo de infusão a vácuo | |
AR081221A1 (es) | Anticuerpos anti gdf8 humano | |
PH12017501029A1 (en) | Biaryl derivative as gpr120 agonist | |
BR122018077504B8 (pt) | métodos para síntese de moduladores seletivos de receptor de esfingosina 1 fosfato | |
BR112012011430A2 (pt) | moduladores de receptor de esfingosina 1 fosfato e métodos de síntese quiral | |
BR112012011431A2 (pt) | moduladores heterocíclicos seletivos de receptor de esfingosina 1 fosfato | |
BR112013006929A2 (pt) | composto de fórmula i, composição farmacêutica, processo para preparar os compostos de fórmula 9, 16, 20, 27 e 30 | |
RU2012130439A (ru) | Композиция балаглитазона и способы ее применения | |
BR112013026413A2 (pt) | sistema de acionamento de dispositivo de medição de sementes | |
WO2011068774A3 (en) | Methods for regulating gelation of hydrogel solutions and uses thereof | |
Nguyen et al. | Synthesis of the bio-based alternative to Bis-GMA and its application to photo-polymerizable adhesives | |
BR112014015841A8 (pt) | composição de resina alquídica compreendendo sílica | |
UA97975C2 (ru) | ЗАМЕЩЕННЫЕ ФЕНОКСИПРОИЗВОДНЫЕ N-АЛКИЛОВАННЫЕ ТИАЗОЛИДИНДИОНЫ КАК МОДУЛЯТОРЫ ЭСТРОГЕН-РОДСТВЕННЫХ РЕЦЕПТОРОВ α | |
BR112012013135A8 (pt) | Composição de resina, processo para preparar um resina de poliésyer com funcionalidade hidroxila e processo para preparar uma composição de resina de poliéster com funcionalidade hidroxila curável | |
Barg et al. | Can a fibular malunion be corrected by a Z-shaped fibular osteotomy? | |
Zhelev et al. | Treatment of Metaphyseal Defects in Plated Proximal Humerus Fractures with a New Augmentation Technique—A Biomechanical Cadaveric Study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |